Federal drug policy rarely bends to grass-roots pressure, yet the kratom industry pulled off one of Washington's most surprising reversals. When the Trump administration backed down from plans to classify kratom's active compounds as Schedule I controlled substances, it wasn't an accident or a sudden change of heart by public health officials. It was the result of an aggressive, well-funded lobbying blitz that outmaneuvered the Drug Enforcement Administration and the Food and Drug Administration at their own game.
Let's be clear about what actually happened behind closed doors. During the Trump presidency, federal health agencies pushed hard to restrict kratom, a Southeast Asian tropical tree whose leaves contain mitragynine and 7-hydroxymitragynine. Those compounds interact with opioid receptors in the brain. The FDA, led at the time by Commissioner Scott Gottlieb, repeatedly warned that kratom had no approved medical uses and carried severe risks of addiction, abuse, and fatal overdose. Behind the scenes, the Department of Health and Human Services even sent a formal recommendation to the DEA to place kratom's main alkaloids into Schedule I—the same restrictive category as heroin and LSD. For an alternative look, see: this related article.
Then the money and the political pressure arrived. And the federal push quietly died.
Why the Federal Ban Stalled
You can't understand this reversal without looking at who stood to lose billions of dollars. By the late 2010s, kratom had grown from an obscure botanical sold in head shops into a massive retail industry across the United States, generating over a billion dollars annually in sales through gas stations, smoke shops, and online vendors. Related insight on this trend has been published by The New York Times.
When federal regulators threatened to wipe out that market overnight, industry leaders didn't just hire standard Washington lobbyists. They hired people with direct lines to the Oval Office and Republican leadership.
According to federal lobbying disclosures and reporting from outlets like The New York Times and STAT, the American Kratom Association (AKA) dramatically ramped up its spending and retained high-profile firms with deep ties to the Trump orbit. One of the most prominent names brought onto the roster was former Trump campaign manager Corey Lewandowski, alongside other well-connected Republican operatives.
Their pitch to the administration wasn't complicated, and it played directly to Trump's populist instincts and skepticism of federal bureaucracy:
- The opioid crisis angle: Lobbyists argued that millions of Americans were using kratom to wean themselves off prescription painkillers and heroin. Banning it, they claimed, would drive desperate people back to deadly street fentanyl.
- The anti-establishment message: They framed the FDA and DEA as overreaching "deep state" regulators trying to criminalize a natural plant and strip away personal freedom from everyday voters, including military veterans suffering from chronic pain and PTSD.
- The political cost: Grassroots advocates flooded congressional offices and the White House switchboard with tens of thousands of calls, warning lawmakers that a ban would trigger massive backlash at the ballot box.
It worked. The HHS scheduling recommendation sat untouched at the DEA for years without ever being acted upon, effectively neutralizing the federal ban without requiring a formal public retreat from the White House.
What Most People Get Wrong About the Kratom Debate
If you listen only to industry advocates, kratom is a harmless coffee relative that saves lives. If you listen only to federal regulators from that era, it's a dangerous street drug masquerading as an herbal supplement. Both sides are leaving out critical context.
Botanically, Mitragyna speciosa really is in the same family as the coffee tree. In small doses, users report mild stimulation, alertness, and elevated mood. At higher doses, however, its alkaloids bind to mu-opioid receptors, producing sedation and pain relief that mimic traditional opioids.
That dual nature is why scientists and addiction specialists remain deeply divided. Dr. Nora Volkow, director of the National Institute on Drug Abuse (NIDA), has pointed out that while kratom shows potential for easing opioid withdrawal symptoms in some individuals, it also carries genuine risks of physical dependence and toxicity. NIDA has funded millions of dollars in research to isolate its compounds and determine whether safe, standardized medications can be developed from the plant.
The real danger in the current unregulated market comes down to two major issues:
- Contamination and adulteration: Because kratom isn't regulated as a drug by the FDA, products sold in convenience stores vary wildly in potency. Federal testing has uncovered batches contaminated with heavy metals like lead and nickel, dangerous bacteria like Salmonella, and synthetic compounds spiked into extracts to make them stronger.
- Concentrated extracts: Chewing raw leaves in Thailand or Malaysia is vastly different from chugging concentrated liquid kratom shots sold at American gas stations. Those shots pack massive doses of 7-hydroxymitragynine, an alkaloid far more potent than morphine in certain animal studies, drastically increasing the risk of dependence and severe withdrawal.
Inside the Industry's Playbook
The kratom lobby didn't just play defense in Washington. They went on offense at the state level to build a regulatory firewall that made a federal crackdown politically toxic.
Instead of fighting all regulation, the American Kratom Association began pushing its own model legislation across state capitals, known as the Kratom Consumer Protection Act (KCPA). On paper, it sounds sensible. The laws typically ban sales to minors, require basic labeling of alkaloid content, and prohibit vendors from mixing kratom with synthetic drugs.
In practice, passing KCPA laws in states like Utah, Georgia, Arizona, and Nevada accomplished something much bigger for the industry. It legitimized kratom as a legal consumer commodity. Once state legislatures voted to regulate and tax kratom rather than ban it, federal officials faced a much steeper climb trying to declare it a Schedule I narcotic with zero accepted value.
Lobbyists also leaned heavily on personal testimonials. They brought military veterans, nurses, and chronic pain patients directly to Capitol Hill and statehouses to testify about how kratom gave them their lives back after prescription opioids ruined them. Lawmakers found it almost impossible to look a disabled veteran in the eye and tell them they were going to make their preferred pain management tool a felony.
The Regulatory Vacuum Left Behind
When the Trump administration backed down, it didn't create a safe, well-regulated market. It created a wild west.
Because the FDA refused to recognize kratom as a legitimate dietary supplement—arguing it falls under rules governing unapproved new drugs—the agency wouldn't set federal manufacturing standards, purity thresholds, or dosing guidelines. Meanwhile, because the DEA wouldn't schedule it, the plant remained completely legal in most of the country.
Consumers are the ones stuck navigating that gray zone. When you walk into a shop today and buy a bag of green Maeng Da powder or a liquid extract shot, there is no federal agency verifying that what's printed on the label matches what's inside the package. You're relying entirely on the integrity of the manufacturer and whether they pay for independent third-party lab testing.
Several lawsuits filed by families of people who died after ingesting concentrated kratom products have highlighted just how little oversight exists. In multiple civil cases, plaintiffs demonstrated that retail products contained dangerously high alkaloid concentrations with zero warnings about addiction or overdose risks on the packaging.
How to Navigate Kratom Safely if You Use It
If you're currently using kratom or considering it for pain or opioid withdrawal, waiting for Washington to sort out its regulatory mess isn't a strategy. Protect yourself by applying strict standards to anything you buy:
- Demand third-party Certificates of Analysis (COAs): Never buy kratom from a vendor that doesn't publish current, batch-specific lab results from an accredited independent laboratory. Verify that the test screens for heavy metals, microbial contamination (Salmonella and E. coli), and exact mitragynine levels.
- Avoid concentrated liquid shots and enhanced extracts: Stick strictly to plain leaf powder or capsules if you use it at all. Concentrated extracts spike tolerance rapidly and carry a much higher risk of physical dependence and harsh withdrawal symptoms.
- Never mix kratom with other substances: The vast majority of kratom-related fatalities documented by the CDC involved polysubstance use—combining kratom with fentanyl, heroin, benzodiazepines, or alcohol.
- Talk openly with a physician: If you're using kratom to manage opioid withdrawal or chronic pain, consult an addiction medicine specialist or primary care doctor about FDA-approved, clinically proven options like buprenorphine that offer predictable dosing and medical supervision.
The kratom industry proved that enough lobbying muscle and grassroots noise can stop a federal ban dead in its tracks, even during an administration that promised a tough-on-drugs crackdown. Until federal regulators and lawmakers establish real safety standards instead of swinging between total prohibition and total neglect, consumers are entirely on their own.